What is ENSC's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ENSC?

P/E (TTM) is n/a and 52-week range is $0.23 to $2.75 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ENSC figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ENSC?

The company profile lists revenue (TTM) near $5M, net income (TTM) near $-1.42B, EPS (TTM) near $-2.75 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Ensysce Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in La Jolla, California, US, 14.7M shares outstanding, ISIN US2936025046 when available from company profile and filing metadata.

Ensysce Biosciences Inc

$ENSC

Health Care · Biotechnology

IR Run Scenarios

$0.53

+15.07%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The company is headquartered in La Jolla, California and currently employs 8 full-time employees. The company went IPO on 2017-12-01. The firm develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

Employees

Website

ensysce.com/

IPO

2017-12-01

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)